United States Department of Veterans Affairs Launches MDMA Trial

The United States — United States Department of Veterans Affairs has launched a new clinical trial to study the safety and efficacy of MDMA-assisted therapy for veterans suffering from post-traumatic stress disorder (PTSD) and alcohol use disorder. This initiative follows an executive order by President Donald Trump to accelerate research into psychedelic treatments for serious mental illnesses. The randomized, placebo-controlled study will enroll approximately 80 veterans at United States — United States Department of Veterans Affairs facilities in Providence, Rhode Island, and West Haven, Connecticut. The United States — Food and Drug Administration has previously granted 'breakthrough therapy' designation to MDMA, indicating its potential, although it declined to approve MDMA-assisted therapy for PTSD in 2024, calling for more research. United States — United States Department of Veterans Affairs Secretary Doug Collins emphasized the importance of exploring new approaches to mental health, and the agency is currently involved in 19 psychedelic-related studies. The trial aims to provide evidence for a treatment that could redefine how trauma is addressed, especially for veterans who have not responded to traditional therapies.